Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil

被引:143
|
作者
Moloney, Gregory [1 ,2 ]
Petsoglou, Constantinos [1 ,2 ]
Ball, Matthew [1 ,2 ]
Kerdraon, Yves [1 ,2 ]
Hollhumer, Roland [1 ]
Spiteri, Natasha [1 ]
Beheregaray, Simone [1 ]
Hampson, Judith [1 ]
D'Souza, Mario [2 ]
Devasahayam, Raj N. [1 ,2 ,3 ]
机构
[1] Univ Sydney, Sydney Med Sch, Discipline Ophthalmol, Sydney, NSW, Australia
[2] Sydney Eye Hosp, Sydney, NSW, Australia
[3] OTDS, Lions NSW Eye Bank, Sydney, NSW, Australia
关键词
Fuchs dystrophy; Descemetorhexis; ripasudil; INHIBITOR EYE DROPS; CORNEAL-DYSTROPHY; KERATOPLASTY; MEMBRANE;
D O I
10.1097/ICO.0000000000001209
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report the safety and efficacy of descemetorhexis without grafting as a primary intervention in Fuchs dystrophy, and the use of a ROCK inhibitor, ripasudil as a salvage agent in failing cases. Methods: Twelve eyes of 11 patients underwent central descemetorhexis not exceeding 4 mm. All had Fuchs dystrophy-producing visual symptoms, requesting intervention. Exclusion criteria were a peripheral endothelial cell count,1000 and central edema. Corneal clearance and visual parameters were recorded monthly until corneal clearance was observed, then at intervals of 6 months. Cases failing to clear by month 2 were considered for salvage treatment. This consisted of treatment with 1 of 2 formulations of Rho-associated kinase inhibitor eye drops. Endothelial keratoplasty was planned as the final salvage procedure in unsuccessful cases. Results: Nine of 12 eyes cleared spontaneously between 2 and 6 months. One eye failed to clear by month 5 and topical Y-27632 was administered, without success. Endothelial keratoplasty was performed. In 2 eyes, healing stalled at 3 and 2 months. In both cases, topical ripasudil administered 6 times a day for 2 weeks resulted in complete corneal clearance. In cases achieving corneal clearance, best spectacle corrected visual acuity improved from a mean of 0.26 to 0.125 (logMAR) with subjective improvement in quality of vision. Conclusions: In Fuchs dystrophy with visual degradation due to central guttae, descemetorhexis without grafting is a viable procedure for visual rehabilitation. Careful patient selection is required, but the advent of topical ripasudil as a salvage agent suggests that a broader application of the surgery may be possible. Further study into the use of this agent is now needed.
引用
收藏
页码:642 / 648
页数:7
相关论文
共 39 条
  • [21] The ROCK-inhibitor ripasudil suppresses the expression of extracellular matrix proteins in Fuchs endothelial corneal dystrophy
    Strunz, Maria
    Zenkel, Matthias
    Schloetzer-Schrehardt, Ursula
    Kruse, Friedrich
    ACTA OPHTHALMOLOGICA, 2022, 100
  • [22] LONG-TERM RESULTS OF CORNEAL GRAFTING IN FUCHS ENDOTHELIAL DYSTROPHY
    OLSEN, T
    EHLERS, N
    FAVINI, E
    ACTA OPHTHALMOLOGICA, 1984, 62 (03): : 445 - 452
  • [23] Feasibility of cell-based therapy combined with descemetorhexis for treating Fuchs endothelial corneal dystrophy in rabbit model
    Okumura, Naoki
    Matsumoto, Daiki
    Fukui, Yuya
    Teramoto, Masataka
    Imai, Hirofumi
    Kurosawa, Tetta
    Shimada, Tomoki
    Kruse, Friedrich
    Schloetzer-Schrehardt, Ursula
    Kinoshita, Shigeru
    Koizumi, Noriko
    PLOS ONE, 2018, 13 (01):
  • [24] Descemet Stripping without Transplantation in Fuchs Endothelial Corneal Dystrophy
    Menzel-Severing, Johannes
    Geerling, Gerd
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2022, 239 (06) : 760 - 765
  • [25] A Case Report Illustrating the Postoperative Course of Descemetorhexis without Endothelial Keratoplasty with Topical Netarsudil Therapy
    Ploysangam, Pimpiroon
    Patel, Sangita P.
    CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2019, 2019
  • [26] Transcorneal freezing and topical Rho-kinase inhibitor treatment in Fuchs endothelial corneal dystrophy
    Johannes Menzel-Severing
    Stefan Schrader
    Ursula Schlötzer-Schrehardt
    Gerd Geerling
    Eye, 2022, 36 : 891 - 893
  • [27] Transcorneal freezing and topical Rho-kinase inhibitor treatment in Fuchs endothelial corneal dystrophy
    Menzel-Severing, Johannes
    Schrader, Stefan
    Schlotzer-Schrehardt, Ursula
    Geerling, Gerd
    EYE, 2022, 36 (04) : 891 - 893
  • [28] Increased corneal endothelial cell migration in Fuchs endothelial corneal dystrophy, with or without TCF4 repeat expansion
    Tone, Stephan Ong
    Wylegala, Adam
    Boehm, Myriam Susanne
    Melangath, Geetha
    Jurkunas, Ula
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [29] Disease Expression and Familial Transmission of Fuchs Endothelial Corneal Dystrophy With and Without CTG18.1 Expansion
    Xu, Timothy T.
    Li, Yi-Ju
    Afshari, Natalie A.
    Aleff, Ross A.
    Rinkoski, Tommy A.
    Patel, Sanjay V.
    Maguire, Leo J.
    Edwards, Albert O.
    Brown, William L.
    Fautsch, Michael P.
    Wieben, Eric D.
    Baratz, Keith H.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (01)
  • [30] Descemet Stripping Without Endothelial Keratoplasty in Early-Stage Central Fuchs Endothelial Dystrophy: Long-term Results
    Vieira, Rita
    Castro, Catarina
    Coelho, Joao
    Neves, Miguel Mesquita
    Gomes, Miguel
    Oliveira, Luis
    CORNEA, 2023, 42 (08) : 980 - 985